多发性骨髓瘤中t(11;14)患病率与疾病生物学的前瞻性真实世界评估:MEDICI研究分析
MEDICI是一项全球、微创、前瞻性研究,评估新诊断多发性骨髓瘤(NDMM)和复发/难治性多发性骨髓瘤(RRMM)中t(11;14)状态。498例患者骨髓FISH检测成功,总体t(11;14)患病率为22.1%(95%CI 18.5-26.0),NDMM为18.8%,RRMM为27.0%。t(11;14)阳性患者在各疾病分期分布均匀,但在非裔美国患者和轻链型疾病中频率更高,且IRF4突变频率更高。
要点
- MEDICI研究显示多发性骨髓瘤中t(11;14)真实世界患病率为22.1%(95%CI 18.5-26.0)。
- RRMM中t(11;14)患病率27.0%,高于NDMM的18.8%。
- t(11;14)阳性患者中非裔美国患者(RRMM OR 7.27)和轻链型疾病(NDMM OR 3.02)频率更高。
核心结论
- MEDICI研究证明使用浆细胞富集FISH可可重复地检测t(11;14),多发性骨髓瘤真实世界患病率为22.1%。
研究设计与样本
- MEDICI是一项全球、微创、前瞻性研究,纳入≥18岁的新诊断或复发/难治性多发性骨髓瘤患者,在诊断和/或复发时采集骨髓穿刺样本。
- 共分析525例患者样本(NDMM n=306,RRMM n=219),其中498例(95%)骨髓FISH检测成功。
主要发现
- 总体t(11;14)患病率为22.1%(110/498例;95%CI 18.5-26.0)。
- NDMM中t(11;14)患病率为18.8%(56/298例;95%CI 14.5-23.7),RRMM中为27.0%(54/200例;95%CI 21.0-33.7)。
- t(11;14)阳性患者在各疾病分期分布均匀:I期24.1%,II期20%,III期21.3%。
- t(11;14)阳性在非裔美国RRMM患者中比值比(OR)为7.27(95%CI 1.33-39.83;P=0.022),在NDMM轻链型疾病中OR为3.02(95%CI 1.33-6.87;P=0.008)。
- 染色体1q异常在无t(11;14)时更常见,而t(11;14)存在时浆细胞分化调节因子IRF4突变频率更高。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Genetic abnormalities in multiple myeloma (MM) influence treatment outcomes and may inform therapeutic decisions. The most common chromosomal translocation in MM is t(11;14); however, its role in disease progression is not well defined. We report results from MEDICI, a global, minimally invasive, prospective study evaluating t(11;14) status in newly diagnosed MM (NDMM) and relapsed/refractory MM (RRMM). MEDICI enrolled adult patients (≥18 years) with MM with bone marrow (BM) aspirates collected at diagnosis and/or disease relapse. The primary objective was to determine t(11;14) prevalence in patient BM samples using fluorescent in situ hybridization (FISH) with plasma cell enrichment. Samples from 525 patients (NDMM, n = 306; RRMM, n = 219) were analyzed for t(11;14), with 498 patients (95%) having successful BM FISH test. Prevalence of t(11;14) was 22.1% (110/498 patients; 95% confidence interval [CI], 18.5-26.0) in the overall patient population, 18.8% (56/298 patients; 95% CI, 14.5-23.7) in NDMM, and 27.0% (54/200 patients; 95% CI, 21.0-33.7) in RRMM. Patients with t(11;14)-positive MM were evenly distributed across disease stages (stage I, 24.1%; stage II, 20%; stage III, 21.3%); however, higher rates were observed in African American patients (RRMM odds ratio [OR], 7.27, 95% CI, 1.33-39.83; P = .022) and light-chain only disease (NDMM OR, 3.02, 95% CI, 1.33-6.87; P = .008). Chromosome 1q abnormalities occurred more often in the absence of t(11;14); however, higher frequency of mutation in the plasma cell differentiation regulator IRF4 was detected in t(11;14) presence. In conclusion, the results from MEDICI demonstrated reproducible t(11;14) detection with a real-world prevalence of 22.1% in MM. This trial was registered at www.ClinicalTrials.gov as #NCT04721002.
引用
- Spencer A, Gavriatopoulou M, Coriu D, et al. Prospective real-world evaluation of t(11;14) prevalence and disease biology in multiple myeloma: MEDICI study analysis. Blood Adv. 2025. PMID: 40829119. doi:10.1182/bloodadvances.2025017214
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。